(BBH) VanEck Biotech - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US92189F7261 • Health
BBH: Biotechnology, Pharmaceuticals, Diagnostics, Therapeutics, Medical Devices
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. ‣ Company URL: http://www.vaneck.com ‣ Domicile: United States
Additional Sources for BBH ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BBH ETF Overview
| Market Cap in USD | 395m |
| Category | Health |
| TER | 0.35% |
| IPO / Inception | 2011-12-20 |
BBH ETF Ratings
| Growth 5y | 14.4% |
| Fundamental | - |
| Dividend | 43.7% |
| Rel. Strength Industry | -108 |
| Analysts | - |
| Fair Price Momentum | 147.60 USD |
| Fair Price DCF | - |
BBH Dividends
| Dividend Yield 12m | 0.77% |
| Yield on Cost 5y | 0.95% |
| Annual Growth 5y | 15.54% |
| Payout Consistency | 56.8% |
BBH Growth Ratios
| Growth Correlation 3m | -74.2% |
| Growth Correlation 12m | 19.1% |
| Growth Correlation 5y | 7.8% |
| CAGR 5y | 4.23% |
| CAGR/Mean DD 5y | 0.23 |
| Sharpe Ratio 12m | -0.35 |
| Alpha | -24.16 |
| Beta | 0.77 |
| Volatility | 20.01% |
| Current Volume | 4.5k |
| Average Volume 20d | 15.3k |
What is the price of BBH stocks?
As of January 23, 2025, the stock is trading at USD 161.84 with a total of 4,500 shares traded.
Over the past week, the price has changed by +1.49%, over one month by +2.23%, over three months by -6.87% and over the past year by -2.13%.
As of January 23, 2025, the stock is trading at USD 161.84 with a total of 4,500 shares traded.
Over the past week, the price has changed by +1.49%, over one month by +2.23%, over three months by -6.87% and over the past year by -2.13%.
Is VanEck Biotech a good stock to buy?
Neither. Based on ValueRay Analyses, VanEck Biotech is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 14.40 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBH as of January 2025 is 147.60. This means that BBH is currently overvalued and has a potential downside of -8.8%.
Neither. Based on ValueRay Analyses, VanEck Biotech is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 14.40 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBH as of January 2025 is 147.60. This means that BBH is currently overvalued and has a potential downside of -8.8%.
Is BBH a buy, sell or hold?
VanEck Biotech has no consensus analysts rating.
VanEck Biotech has no consensus analysts rating.
What are the forecast for BBH stock price target?
According to ValueRays Forecast Model, BBH VanEck Biotech will be worth about 162.9 in January 2026. The stock is currently trading at 161.84. This means that the stock has a potential upside of +0.64%.
According to ValueRays Forecast Model, BBH VanEck Biotech will be worth about 162.9 in January 2026. The stock is currently trading at 161.84. This means that the stock has a potential upside of +0.64%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 162.9 | 0.6% |